CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2018
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2018
SUMMARY
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) pipeline Target constitutes close to 18 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report CD40 Ligand - Pipeline Review, H2 2, outlays comprehensive information on the CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - CD40 ligand or CD40L is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily. The CD40-CD40 ligand interaction is crucial to the development of T dependent immune responses. The ligand is expressed on a range of cell types including B cells, granulocytes, macrophages and platelets. T cells expressing CD40L provide signals to B cells that induce proliferation, immunoglobulin class switching, antibody secretion, and rescue from apoptosis at different times during the life of a B cell and also have a role in the development of germinal centres and the survival of memory B cells. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 11 respectively.
Similarly, the universities portfolio in Phase II and Preclinical stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System and Infectious Disease which include indications Graft Versus Host Disease (GVHD), Amyotrophic Lateral Sclerosis, Autoimmune Disorders, Breast Cancer, Bladder Cancer, Glioblastoma Multiforme (GBM), Hepatitis B, Hepatocellular Carcinoma, Inflammation, Lung Adenocarcinoma, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Rheumatoid Arthritis, Sicca Syndrome (Sjogren), Solid Tumor and Systemic Lupus Erythematosus.
Furthermore, this report also reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) pipeline Target constitutes close to 18 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report CD40 Ligand - Pipeline Review, H2 2, outlays comprehensive information on the CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - CD40 ligand or CD40L is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily. The CD40-CD40 ligand interaction is crucial to the development of T dependent immune responses. The ligand is expressed on a range of cell types including B cells, granulocytes, macrophages and platelets. T cells expressing CD40L provide signals to B cells that induce proliferation, immunoglobulin class switching, antibody secretion, and rescue from apoptosis at different times during the life of a B cell and also have a role in the development of germinal centres and the survival of memory B cells. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 11 respectively.
Similarly, the universities portfolio in Phase II and Preclinical stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System and Infectious Disease which include indications Graft Versus Host Disease (GVHD), Amyotrophic Lateral Sclerosis, Autoimmune Disorders, Breast Cancer, Bladder Cancer, Glioblastoma Multiforme (GBM), Hepatitis B, Hepatocellular Carcinoma, Inflammation, Lung Adenocarcinoma, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Rheumatoid Arthritis, Sicca Syndrome (Sjogren), Solid Tumor and Systemic Lupus Erythematosus.
Furthermore, this report also reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)
- The report reviews CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics and enlists all their major and minor projects
- The report assesses CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Overview
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Companies Involved in Therapeutics Development
DNAtrix Inc
eTheRNA Immunotherapies NV
Sanofi
TILT Biotherapeutics Ltd
UCB SA
XL-protein GmbH
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drug Profiles
AT-1501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dapirolizumab pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Delta-24-RGDOX - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ECI-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Proteins for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target CD40 Ligand for Malignant Melanoma and Bladder Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis B vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INX-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISF-35 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
letolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LOAd-700 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NJA-730 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TDI-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TILT-234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIB-4920 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Dormant Products
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Product Development Milestones
Featured News & Press Releases
May 24, 2018: eTheRNA Enrols First Patient in High Dose Cohort of Phase 1b study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma
Mar 19, 2018: eTheRNA completes enrolment of low dose cohort for Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma
Jun 30, 2017: etherna Advances in-vivo MRNA Cancer Immunotherapy Into First Oncology Clinical Studies
Jun 08, 2016: UCB presents Phase 1 results for dapirolizumab pegol at the Annual European Congress of Rheumatology (EULAR 2016)
Nov 17, 2015: Memgen Announces Preclinical Results for ISF35 in Combination with Checkpoint Inhibitors in a Model of Metastatic Melanoma
Dec 19, 2011: ALS Therapy Development Institute Announces Research Agreement With Biogen Idec And UCB To Investigate Role Of CD40L In ALS
Dec 07, 2011: Memgen Announces Upcoming Presentation For ISF35 In Chronic Lymphocytic Leukemia At 2011 ASH Annual Meeting
Jun 21, 2011: Memgen Presents Clinical Results For ISF35 In Chronic Lymphocytic Leukemia At ASCO 2011
Dec 09, 2010: Memgen Announces Clinical And Preclinical Results For ISF35 In Chronic Lymphocytic Leukemia And Non-Hodgkin's Lymphoma
Dec 08, 2009: Memgen Announces Positive Data Results Of ISF35 For Chronic Lymphocytic Leukemia
Dec 08, 2009: Memgen's ISF35 Sensitizes Cancer Cells To Chemotherapy
Dec 02, 2009: Memgen Selects Clinical Trial Results Of ISF35 For An Oral Presentation At ASH 2009 Annual Meeting
Dec 01, 2009: Memgen's Clinical Trial Results Of ISF35 For Chronic Lymphocytic Leukemia Selected For Presentation At ASH 2009 Annual Meeting
Jun 08, 2009: Memgen Reports Positive Results For ISF35 In High-Risk Chronic Lymphocytic Leukemia
Jun 04, 2009: Memgen Reports Positive Results For ISF35 In High-Risk Chronic Lymphocytic Leukemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Overview
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Companies Involved in Therapeutics Development
DNAtrix Inc
eTheRNA Immunotherapies NV
Sanofi
TILT Biotherapeutics Ltd
UCB SA
XL-protein GmbH
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drug Profiles
AT-1501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dapirolizumab pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Delta-24-RGDOX - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ECI-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Proteins for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target CD40 Ligand for Malignant Melanoma and Bladder Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis B vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INX-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISF-35 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
letolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LOAd-700 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NJA-730 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TDI-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TILT-234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIB-4920 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Dormant Products
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Product Development Milestones
Featured News & Press Releases
May 24, 2018: eTheRNA Enrols First Patient in High Dose Cohort of Phase 1b study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma
Mar 19, 2018: eTheRNA completes enrolment of low dose cohort for Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma
Jun 30, 2017: etherna Advances in-vivo MRNA Cancer Immunotherapy Into First Oncology Clinical Studies
Jun 08, 2016: UCB presents Phase 1 results for dapirolizumab pegol at the Annual European Congress of Rheumatology (EULAR 2016)
Nov 17, 2015: Memgen Announces Preclinical Results for ISF35 in Combination with Checkpoint Inhibitors in a Model of Metastatic Melanoma
Dec 19, 2011: ALS Therapy Development Institute Announces Research Agreement With Biogen Idec And UCB To Investigate Role Of CD40L In ALS
Dec 07, 2011: Memgen Announces Upcoming Presentation For ISF35 In Chronic Lymphocytic Leukemia At 2011 ASH Annual Meeting
Jun 21, 2011: Memgen Presents Clinical Results For ISF35 In Chronic Lymphocytic Leukemia At ASCO 2011
Dec 09, 2010: Memgen Announces Clinical And Preclinical Results For ISF35 In Chronic Lymphocytic Leukemia And Non-Hodgkin's Lymphoma
Dec 08, 2009: Memgen Announces Positive Data Results Of ISF35 For Chronic Lymphocytic Leukemia
Dec 08, 2009: Memgen's ISF35 Sensitizes Cancer Cells To Chemotherapy
Dec 02, 2009: Memgen Selects Clinical Trial Results Of ISF35 For An Oral Presentation At ASH 2009 Annual Meeting
Dec 01, 2009: Memgen's Clinical Trial Results Of ISF35 For Chronic Lymphocytic Leukemia Selected For Presentation At ASH 2009 Annual Meeting
Jun 08, 2009: Memgen Reports Positive Results For ISF35 In High-Risk Chronic Lymphocytic Leukemia
Jun 04, 2009: Memgen Reports Positive Results For ISF35 In High-Risk Chronic Lymphocytic Leukemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by DNAtrix Inc, H2 2018
Pipeline by eTheRNA Immunotherapies NV, H2 2018
Pipeline by Sanofi, H2 2018
Pipeline by TILT Biotherapeutics Ltd, H2 2018
Pipeline by UCB SA, H2 2018
Pipeline by XL-protein GmbH, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by DNAtrix Inc, H2 2018
Pipeline by eTheRNA Immunotherapies NV, H2 2018
Pipeline by Sanofi, H2 2018
Pipeline by TILT Biotherapeutics Ltd, H2 2018
Pipeline by UCB SA, H2 2018
Pipeline by XL-protein GmbH, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
DNAtrix Inc
eTheRNA Immunotherapies NV
Sanofi
TILT Biotherapeutics Ltd
UCB SA
XL-protein GmbH
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
DNAtrix Inc
eTheRNA Immunotherapies NV
Sanofi
TILT Biotherapeutics Ltd
UCB SA
XL-protein GmbH
